Appendix A: Cleaning procedure

For the best results, it is recommended that this procedure be completed before the use of the Biotage® PrepXpert-8 each day and at the end of each extraction prior to proceeding with the next set of samples.

1. Ensure that an empty cleaning cartridge and sample bottle are installed onto each position of the Biotage® PrepXpert-8.
2. Load and run the cleaning method outlined in table 5 below.
3. Remove the cleaning cartridge and sample bottles, disposing of the remaining solvent from the sample bottles.
4. Using methanol in a squeeze bottle, clean the adapters, sample bottle rinse heads, and the sip tubes.

Note: In situations where the previous sample was highly concentrated, the above cleaning procedure may need to be repeated multiple times. If there is concern regarding potential carryover contamination regardless of the cleaning procedure, a laboratory reagent blank should be run in that position to ensure its cleanliness.

Table 5. Cleaning parameters

Operation	Amount (mL)	Input	Output	Flow (mL/min)
Rinse	5	MeOH	Sample Rinse	60
Pump	2.5	MeOH	Sample	15
Pump	2.5	MeOH	Sample	15
Pump	5	Water	Sample	15
Pump	5	MeOH	Solvent waste	15
Pump	5	MeOH	Solvent waste	15
Dry	10 sec	Nitrogen	Solvent waste	-

© Biotage 2025

Appendix B: MRM transitions

Table 6. MRM transitions for Agilent 6470 MS/MS

Compound name	Precursor ion	Product ion	Fragmentor (V)	Collision energy (V)	Cell acc (V)	Ret time (min)	Ret window	Polarity
11Cl-PF3OUdS	630.9	450.9	165	32	5	18	1	Negative
11Cl-PF3OUdS	630.9	82.9	165	32	5	18	1	Negative
4:2FTS	327	306.9	125	20	5	9.71	1	Negative
4:2FTS	327	80.9	125	36	5	9.71	1	Negative
6:2FTS	427	406.8	125	24	5	13.6	1	Negative
6:2FTS	427	80.9	125	40	5	13.6	1	Negative
8:2FTS	527	506.8	170	28	5	16.39	1	Negative
8:2FTS	527	80.9	170	40	5	16.39	1	Negative
9Cl-PF3ONS	530.9	350.9	145	28	5	15.9	1	Negative
9Cl-PF3ONS	530.9	83	145	32	5	15.9	1	Negative
ADONA	377	250.9	80	12	5	12.27	1	Negative
ADONA	377	85	80	36	5	12.27	1	Negative
C2-4:2FTS	329	309	125	20	5	9.71	1	Negative
C2-6:2FTS	429	409	125	24	5	13.6	1	Negative
C2-8:2FTS	529	509	170	28	5	16.39	1	Negative
C2-PFDoA	614.9	570	79	5	5	18.43	1	Negative
C2-PFOA	415	369.9	80	8	5	13.7	1	Negative
C2-PFOA	415	168.9	80	20	5	13.7	1	Negative
C3-HFPO-DA	287	184.9	160	20	5	10.6	1	Negative
C3-HFPO-DA	287	168.9	160	4	5	10.6	1	Negative
C3-PFBA	216	171.9	65	8	5	5.42	1	Negative

© Biotage 2025

Compound name	Precursor ion	Product ion	Fragmen-tor (V)	Collision energy (V)	Cell acc (V)	Ret time (min)	Ret window	Polarity
C3-PFBS	302	80	100	45	5	8.11	1	Negative
C3-PFHxS	402	80	100	45	5	12.12	1	Negative
C4-PFBA	217	172	60	8	5	5.42	1	Negative
C4-PFHpA	367	322	72	0	5	11.96	1	Negative
C4-PFOS	502.9	98.9	180	48	5	15.18	1.2	Negative
C4-PFOS	502.9	79.9	180	52	5	15.18	1.2	Negative
C5-PFHxA	318	273	70	8	5	9.91	1	Negative
C5-PFPeA	268	223	60	8	5	7.64	1	Negative
C6-PFDA	519	474	81	4	5	16.42	1	Negative
C7-PFUnA	570	525	73	5	5	17.49	1	Negative
C8-PFOA	421	376	69	4	5	13.7	1	Negative
C8-PFOS	507	80	100	50	5	15.18	1.2	Negative
C9-PFNA	472	427	66	4	5	15.17	1	Negative
HFPO-DA-CO2	285	184.9	155	16	5	10.59	1	Negative
HFPO-DA-CO2	285	168.9	155	4	5	10.59	1	Negative
NFDHA	295	201	75	5	5	9.57	1	Negative
NFDHA-CO2	251	84.9	130	20	5	12.28	2	Negative
PFBA	213	168.9	60	8	5	5.41	1	Negative
PFBS	298.9	98.9	100	29	5	8.1	1	Negative
PFBS	298.9	80	100	45	5	8.1	1	Negative
PFDA	513	469	81	4	5	16.42	1	Negative
PFDA	513	218.7	100	16	5	16.42	1	Negative
PFDoA	613	569	79	5	5	18.43	1	Negative

© Biotage 2025

Compound name	Precursor ion	Product ion	Fragmen-tor (V)	Collision energy (V)	Cell acc (V)	Ret time (min)	Ret window	Polarity
PFDoA	613	268.7	100	20	5	18.43	1	Negative
PFEESA	314.9	134.9	110	24	5	9.03	1	Negative
PFEESA	314.9	69	110	60	5	9.03	1	Negative
PFHpA	362.9	319	72	0	5	11.97	1	Negative
PFHpA	362.9	169	72	12	5	11.97	1	Negative
PFHpS	448.9	98.7	100	44	5	13.77	1	Negative
PFHpS	448.9	79.7	100	52	5	13.77	1	Negative
PFHxA	313	268.9	70	8	5	9.91	1	Negative
PFHxA	313	119	70	18	5	9.91	1	Negative
PFHxS	398.9	99	100	45	5	12.12	1.5	Negative
PFHxS	398.9	80	100	49	5	12.12	1.5	Negative
PFMBA	279	84.9	70	12	5	8.36	1	Negative
PFMPA	229	84.9	60	12	5	6.27	1	Negative
PFNA	463	419	66	4	5	15.17	1	Negative
PFNA	463	219	66	17	5	15.17	1	Negative
PFOA	413	369	69	4	5	13.7	1	Negative
PFOA	413	169	69	12	5	13.7	1	Negative
PFOS	498.9	99	100	50	5	15.18	1.5	Negative
PFOS	498.9	80	100	50	5	15.18	1.5	Negative
PFPeA	263	218.9	60	8	5	7.64	1	Negative
PFPeS	348.9	98.9	135	40	5	10.21	1	Negative
PFPeS	348.9	79.9	135	40	5	10.21	1	Negative
PFUnA	563	519	73	5	5	17.49	1	Negative
PFUnA	563	269	100	20	5	17.49	1	Negative

© Biotage 2025

Appendix C: Calibration curves

Calibration curves for the target analytes in Table 1, covering a concentration range of 0.2-100 ppt.

PFBA



NFDHA



PFMPA



4:2 FTS



PFPeA



4:2 FTS



PFBS



PFPeS



PFMBA



HFPO-DA



PFEESA



PFHpA



© Biotage 2025

PFHxS



8:2 FTS



ADONA



PFDA



6:2 FTS



PFUnA



PFHpS



11Cl-PF3OUdS



PFNA



PFDoA



9Cl-PF3ONS



© Biotage 2025

Appendix D: MRL and DL data

Table 7. MRL and DL Recoveries for EVOLUTE® PFAS 533 200 mg/6 mL cartridge.

	Conc.	1	2	3	4	5	6	7	8	9	10	Average	Std Dev	HRPIR	Lower PIR	Upper PIR	DL
	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(%)	(%)	(ng/L)
PFBA	2.00	2.38	2.26	2.23	2.35	2.23	2.24	2.28	2.28	2.19	2.20	2.27	0.06	0.20	103.5	123.0	0.17
PFMPA	2.00	1.92	1.83	1.79	1.92	1.81	1.86	1.79	1.81	1.79	1.74	1.83	0.06	0.19	82.0	100.7	0.16
PFPeA	2.00	2.01	1.91	1.87	1.95	1.82	1.87	1.89	1.88	1.77	1.79	1.88	0.07	0.23	82.4	105.3	0.20
PFBS*	1.77	1.79	1.72	1.77	1.82	1.66	1.80	1.76	1.72	1.69	1.64	1.74	0.06	0.20	76.8	96.9	0.18
PFMBA	2.00	1.95	1.85	1.72	1.90	1.78	1.80	1.86	1.79	1.76	1.74	1.81	0.07	0.24	78.9	102.6	0.21
PFEESA*	1.78	1.57	1.47	1.43	1.51	1.45	1.47	1.46	1.45	1.38	1.41	1.46	0.05	0.17	64.5	81.7	0.15
NFDHA	2.00	2.02	1.86	1.91	1.98	1.89	2.00	1.97	1.99	1.62	1.69	1.89	0.14	0.44	72.9	116.5	0.38
4:2 FTS*	1.88	1.95	1.87	1.78	1.86	1.77	1.88	1.79	1.74	1.77	1.73	1.81	0.07	0.23	79.3	102.0	0.20
PFHxA	2.00	1.95	1.84	1.86	2.00	1.88	1.89	1.94	1.88	1.82	1.78	1.88	0.06	0.20	84.1	104.3	0.18
PFPeS*	1.88	1.83	1.63	1.61	1.77	1.76	1.74	1.70	1.74	1.61	1.60	1.70	0.08	0.26	72.1	97.9	0.23
HFPO-DA	2.00	2.06	2.08	2.06	1.96	2.04	2.41	2.01	1.96	2.06	2.05	2.07	0.13	0.40	83.3	123.6	0.35
PFHpA	2.00	2.15	2.02	1.95	2.12	1.95	2.06	2.06	1.94	1.91	1.85	2.00	0.10	0.31	84.3	115.7	0.28
PFHxS*	1.83	1.84	1.72	1.73	1.76	1.75	1.81	1.83	1.65	1.66	1.66	1.74	0.07	0.23	75.8	98.3	0.20
ADONA*	1.89	1.84	1.69	1.72	1.83	1.72	1.77	1.70	1.68	1.69	1.68	1.73	0.06	0.19	76.8	96.3	0.17
6:2 FTS*	1.90	2.04	1.92	1.75	1.79	1.67	1.85	1.88	1.91	1.96	1.72	1.85	0.12	0.37	73.8	111.1	0.33
PFOA	2.00	2.06	2.10	2.01	2.10	2.04	2.11	2.05	2.02	1.96	2.04	2.05	0.05	0.15	94.9	109.9	0.13
PFHpS*	1.91	1.89	1.75	1.73	1.72	1.69	1.70	1.76	1.63	1.73	1.65	1.73	0.07	0.23	75.0	97.6	0.20
PFNA	2.00	2.10	2.03	1.91	2.04	2.03	1.97	2.05	1.94	1.97	1.91	1.99	0.07	0.21	89.2	110.2	0.19
PFOS*	1.86	2.02	1.78	1.81	1.81	1.90	1.81	1.86	1.79	1.78	1.84	1.84	0.07	0.24	80.1	103.9	0.21
9Cl-PF3ONS*	1.87	1.85	1.76	1.71	1.82	1.75	1.78	1.68	1.78	1.65	1.70	1.75	0.06	0.20	77.2	97.7	0.18
8:2 FTS*	1.92	1.99	1.83	1.78	1.93	1.84	1.93	1.81	1.97	1.77	1.81	1.86	0.08	0.26	80.2	106.3	0.23
PFDA	2.00	1.83	1.91	1.87	1.92	1.80	1.90	1.91	1.85	1.79	1.70	1.85	0.07	0.22	81.4	103.4	0.19
PFUnA	2.00	2.06	1.90	1.90	2.01	1.90	1.91	1.93	1.96	1.90	1.93	1.94	0.05	0.18	88.2	105.8	0.15
11Cl-PF3OUdS*	1.89	1.83	1.70	1.63	1.76	1.62	1.66		1.67	1.52	1.58	1.66	0.09	0.31	67.4	98.9	0.26
PFDoA	2.00	1.99	1.86	1.77	1.95	1.79	1.87	1.89	1.88	1.85	1.76	1.86	0.07	0.24	81.2	104.9	0.21

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage 2025

Table 8. MRL and DL Recoveries for EVOLUTE® PFAS 533
500 mg/6 mL cartridge.

	Conc.	1	2	3	4	5	6	7	8	9	10	Average	Std Dev	HRPIR	Lower PIR	Upper PIR	DL
	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(%)	(%)	(ng/L)
PFBA	2.00	2.18	2.14	2.11	2.07	2.14	2.10	2.10	2.10	2.17	2.04	2.12	0.04	0.14	98.6	113.0	0.13
PFMPA	2.00	2.10	2.04	2.09	1.97	1.98	1.96	1.92	1.92	2.09	1.95	2.00	0.07	0.23	88.8	111.5	0.20
PFPeA	2.00	2.05	1.99	1.99	1.93	1.93	1.94	1.91	1.95	2.05	1.87	1.96	0.06	0.19	88.6	107.6	0.17
PFBS*	1.77	1.84	1.79	1.76	1.71	1.72	1.74	1.67	1.71	1.87	1.67	1.75	0.07	0.22	76.6	98.3	0.19
PFMBA	2.00	2.35	2.28	2.15	2.15	2.21	2.20	2.19	2.19	2.24	2.04	2.20	0.08	0.26	96.8	122.9	0.23
PFEESA*	1.78	1.77	1.70	1.65	1.64	1.66	1.65	1.60	1.63	1.68	1.56	1.66	0.06	0.18	73.6	92.0	0.16
NFDHA	2.00	2.05	2.04	2.18	2.00	1.85	1.92	1.97	2.03	2.07	1.95	2.00	0.09	0.29	85.6	114.8	0.26
4:2 FTS*	1.88	2.00	1.92	1.97	1.88	1.83	1.89	1.87	1.85	1.96	1.76	1.89	0.07	0.24	82.9	106.4	0.21
PFHxA	2.00	2.06	2.03	1.94	1.93	1.94	1.96	1.92	1.93	2.04	1.89	1.96	0.06	0.19	88.8	107.6	0.17
PFPeS*	1.88	1.90	1.90	1.92	1.81	1.87	1.83	1.80	1.81	1.91	1.84	1.86	0.05	0.15	85.3	100.5	0.13
HFPO-DA	2.00	1.90	2.11	2.01	2.01	1.90	1.91	1.87	2.03	1.97	1.81	1.95	0.09	0.29	83.0	112.2	0.26
PFHpA	2.00	2.03	2.03	1.98	1.96	1.94	1.98	1.94	1.96	2.08	1.95	1.98	0.05	0.15	91.6	106.9	0.13
PFHxS*	1.83	1.94	1.87	1.77	1.77	1.81	1.84	1.79	1.77	1.88	1.76	1.82	0.06	0.20	81.1	100.9	0.17
ADONA*	1.89	1.88	1.88	1.81	1.73	1.81	1.81	1.74	1.77	1.84	1.77	1.80	0.05	0.17	81.7	98.7	0.15
6:2 FTS*	1.90	2.00	1.97	1.92	1.81	1.88	1.89	1.92	1.81	1.89	1.76	1.88	0.07	0.24	82.4	106.0	0.21
PFOA	2.00	2.08	2.01	2.00	1.97	2.04	2.09	1.95	2.01	2.00	1.92	2.01	0.05	0.17	91.6	109.0	0.15
PFHpS*	1.91	1.93	1.88	1.82	1.70	2.10	1.75	1.81	1.83	1.84	1.87	1.85	0.11	0.35	75.4	110.1	0.30
PFNA	2.00	2.10	1.94	1.97	1.92	1.99	2.01	1.92	1.99	2.15	1.89	1.99	0.08	0.26	86.3	112.5	0.23
PFOS*	1.86	2.00	1.93	1.86	1.85	1.90	1.92	1.88	1.83	1.91	1.80	1.89	0.06	0.19	85.2	103.7	0.16
9Cl-PF3ONS*	1.87	1.67	1.80	1.78	1.70	1.60	1.73	1.66	1.70	1.79	1.68	1.71	0.06	0.21	75.3	95.8	0.18
8:2 FTS*	1.92	1.92	1.90	1.88	1.76	1.90	1.91	1.82	1.89	1.94	1.92	1.88	0.06	0.18	85.3	103.0	0.16
PFDA	2.00	2.04	2.05	1.91	1.88	1.96	1.88	1.88	1.90	1.98	1.94	1.94	0.06	0.20	87.0	107.2	0.18
PFUnA	2.00	2.07	2.02	2.10	1.93	2.03	2.01	1.91	1.96	1.99	1.94	2.00	0.06	0.20	90.0	109.6	0.17
11Cl-PF3OUdS*	1.89		1.84	1.80	1.71		1.75	1.69	1.68	1.84	1.73	1.76	0.07	0.24	75.5	100.0	0.20
PFDoA	2.00	2.00	2.02	1.99	1.93	2.00	1.88	1.83	1.91	2.01	1.83	1.94	0.07	0.24	85.2	109.1	0.21

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage 2025

Appendix E: Demonstration of precision and accuracy

Table 9. Results of IDP and IDA for EVOLUTE® PFAS 533 200 mg/6 mL cartridge (20 ng/L, n=4).

Replicate	1	2	3	4	Average	Std Dev	RSD
	(%)	(%)	(%)	(%)	(%)	(%)	(%)
PFBA	96.8	91.0	91.5	90.1	92.3	3.0	3.3
PFMPA	88.2	85.6	84.5	85.7	86.0	1.5	1.8
PFPeA	94.4	90.6	90.2	89.7	91.2	2.1	2.3
PFBS*	97.8	93.4	92.0	93.3	94.1	2.5	2.7
PFMBA	90.1	86.9	86.1	86.4	87.4	1.8	2.1
PFEESA*	83.6	81.1	81.4	80.5	81.6	1.4	1.7
NFDHA	97.0	98.8	93.6	91.7	95.3	3.2	3.4
4:2 FTS*	94.0	91.6	90.8	89.7	91.5	1.9	2.0
PFHxA	93.5	91.4	89.7	92.1	91.7	1.6	1.7
PFPeS*	93.2	89.2	95.4	89.2	91.8	3.1	3.4
HFPO-DA	92.9	98.4	86.5	93.6	92.8	4.9	5.3
PFHpA	94.9	94.7	92.1	90.9	93.1	2.0	2.2
PFHxS*	96.0	91.2	96.8	91.5	93.9	2.9	3.1
ADONA*	94.0	90.9	87.8	89.1	90.4	2.7	2.9
6:2 FTS*	96.2	91.8	93.9	89.3	92.8	2.9	3.2
PFOA	95.7	90.3	93.8	90.3	92.5	2.7	2.9
PFHpS*	87.7	87.6	87.6	86.5	87.4	0.6	0.6
PFNA	96.9	95.7	93.8	93.6	95.0	1.6	1.7
PFOS*	95.0	90.7	91.3	90.5	91.9	2.1	2.3
9Cl-PF3ONS*	94.9	91.8	87.9	88.9	90.9	3.2	3.5
8:2 FTS*	96.5	90.1	92.2	90.2	92.2	3.0	3.2
PFDA	89.5	91.5	89.9	88.8	89.9	1.1	1.2
PFUnA	95.5	91.0	92.3	93.0	92.9	1.9	2.1
11Cl-PF3OUdS*	91.9	90.5	85.4	86.5	88.6	3.1	3.5
PFDoA	91.4	89.3	85.7	87.8	88.5	2.4	2.7

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage 2025

Table 10. Results of IDP and IDA for EVOLUTE® PFAS 533 500 mg/6 mL cartridge (20 ng/L, n=4).

Replicate	1	2	3	4	Average	Std Dev	RSD
	(%)	(%)	(%)	(%)	(%)	(%)	(%)
PFBA	99.3	100.3	97.3	96.1	98.3	1.9	1.9
PFMPA	99.5	101.8	97.4	100.1	99.7	1.8	1.8
PFPeA	96.5	99.4	95.7	94.8	96.6	2.0	2.0
PFBS*	95.4	98.1	98.1	91.1	95.7	3.3	3.5
PFMBA	103.6	106.3	103.1	95.9	102.2	4.4	4.4
PFEESA*	98.6	98.8	99.8	92.3	97.4	3.4	3.5
NFDHA	98.2	101.1	100.9	93.5	98.4	3.5	3.6
4:2 FTS*	98.6	101.0	95.2	92.6	96.8	3.7	3.8
PFHxA	98.7	99.5	95.6	93.5	96.8	2.8	2.9
PFPeS*	101.0	100.0	93.9	93.3	97.1	4.1	4.2
HFPO-DA	92.0	86.6	98.9	85.6	90.8	6.1	6.7
PFHpA	100.2	93.0	95.5	94.1	95.7	3.2	3.3
PFHxS*	97.7	98.6	94.7	90.7	95.4	3.6	3.7
ADONA*	97.7	96.3	95.0	91.1	95.0	2.8	3.0
6:2 FTS*	98.3	99.9	94.5	93.7	96.6	3.0	3.1
PFOA	95.7	100.7	91.6	91.0	94.7	4.5	4.7
PFHpS*	93.7	96.3	93.7	94.7	94.6	1.2	1.3
PFNA	98.2	101.5	96.7	91.2	96.9	4.3	4.5
PFOS*	92.4	97.2	92.5	92.0	93.5	2.4	2.6
9Cl-PF3ONS*	94.1	95.8	92.2	91.8	93.5	1.9	2.0
8:2 FTS*	102.9	97.9	96.9	94.0	97.9	3.7	3.8
PFDA	94.8	96.6	94.5	95.1	95.3	1.0	1.0
PFUnA	96.8	99.4	95.1	94.6	96.5	2.2	2.3
11Cl-PF3OUdS*	97.4	96.0	92.6	93.5	94.9	2.2	2.3
PFDoA	97.6	92.2	95.3	92.3	94.4	2.6	2.8

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage 2025

Appendix F: PFAS background study

Table 11. Demonstration of low PFAS background contribution from TurboVap® LV and EVOLUTE® PFAS 533 500 mg/6 mL cartridge.

	TurboVap® LV				EVOLUTE® PFAS 533 cartridge			
Replicate	**1**	**2**	**3**	**4**	**1**	**2**	**3**	**4**
PFBA	0.03	0.04	0.03	0.05	0.04	0.03	0.06	0.05
PFMPA	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00
PFPeA	0.00	0.03	0.01	0.00	0.00	0.00	0.00	0.00
PFBS*	0.00	0.02	0.01	0.00	0.00	0.00	0.00	0.00
PFMBA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFEESA*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NFDHA	0.00	0.05	0.00	0.00	0.00	0.00	0.00	0.00
4:2 FTS*	0.01	0.06	0.00	0.00	0.00	0.00	0.00	0.00
PFHxA	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00
PFPeS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
HFPO-DA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFHpA	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00
PFHxS*	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00
ADONA*	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6:2 FTS*	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00
PFOA	0.00	0.05	0.00	0.00	0.03	0.02	0.01	0.00
PFHpS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFNA	0.00	0.06	0.00	0.00	0.00	0.01	0.00	0.00
PFOS*	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00
9Cl-PF3ONS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8:2 FTS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFUnA	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11Cl-PF3OUdS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFDoA	0.00	0.01	0.00	0.00	0.03	0.03	0.00	0.00

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage 2025

Table 12. Demonstration of low PFAS background contribution from the Biotage® PrepXpert-8.

	Biotage® PrepXpert-8 blanks							
Replicate	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**
PFBA	0.01	0.02	0.00	0.04	0.04	0.08	0.06	0.07
PFMPA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFPeA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFBS*	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.03
PFMBA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFEESA*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NFDHA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4:2 FTS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFHxA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFPeS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
HFPO-DA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFHpA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFHxS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ADONA*	0.00	0.01	0.00	0.00	0.00	0.01	0.01	0.01
6:2 FTS*	0.03	0.03	0.03	0.03	0.07	0.06	0.03	0.08
PFOA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFHpS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFNA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFOS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9Cl-PF3ONS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8:2 FTS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFUnA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11Cl-PF3OUdS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFDoA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage 2025

Table 13. Results of RWB samples for EVOLUTE® PFAS 533 200 mg/6 mL and 500 mg/6 mL cartridge. (recoveries in ng/L).

	200 mg/6 mL				500 mg/6 mL			
Replicate	**1**	**2**	**3**	**4**	**1**	**2**	**3**	**4**
PFBA	0.04	0.05	0.03	0.03	0.03	0.03	0.03	0.04
PFMPA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFPeA	0.03	0.04	0.04	0.03	0.03	0.03	0.04	0.03
PFBS*	0.01	0.01	0.02	0.01	0.03	0.02	0.03	0.01
PFMBA	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFEESA*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NFDHA	0.11	0.06	0.06	0.14	0.11	0.19	0.03	0.12
4:2 FTS*	0.03	0.04	0.03	0.03	0.03	0.04	0.04	0.04
PFHxA	0.02	0.00	0.02	0.02	0.01	0.03	0.02	0.02
PFPeS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
HFPO-DA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFHpA	0.02	0.02	0.04	0.02	0.02	0.02	0.02	0.02
PFHxS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ADONA*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6:2 FTS*	0.00	0.07	0.00	0.00	0.00	0.00	0.00	0.00
PFOA	0.04	0.05	0.03	0.05	0.06	0.10	0.07	0.07
PFHpS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFNA	0.04	0.05	0.04	0.05	0.04	0.05	0.04	0.04
PFOS*	0.03	0.06	0.03	0.04	0.05	0.09	0.04	0.05
9Cl-PF3ONS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8:2 FTS*	0.02	0.02	0.04	0.04	0.06	0.01	0.04	0.07
PFDA	0.01	0.01	0.01	0.01	0.02	0.00	0.00	0.00
PFUnA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11Cl-PF3OUdS*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PFDoA	0.02	0.01	0.01	0.02	0.03	0.02	0.01	0.02

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage 2025

Table 14. Results of carryover study of RWB samples using EVOLUTE® PFAS 533 500 mg/6 mL cartridge following four 100 ng/L LFB samples being extracted through system.

Replicate	1	2	3	4	Average
	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)
PFBA	0.14	0.14	0.15	0.17	0.15
PFMPA	0.01	0.00	0.00	0.00	0.00
PFPeA	0.03	0.03	0.03	0.04	0.03
PFBS*	0.03	0.02	0.01	0.02	0.02
PFMBA	0.01	0.01	0.00	0.00	0.01
PFEESA*	0.00	0.01	0.00	0.00	0.00
NFDHA	0.09	0.10	0.07	0.13	0.10
4:2 FTS*	0.04	0.04	0.03	0.05	0.04
PFHxA	0.03	0.03	0.03	0.02	0.03
PFPeS*	0.01	0.03	0.00	0.00	0.01
HFPO-DA	0.00	0.00	0.00	0.00	0.00
PFHpA	0.03	0.05	0.03	0.03	0.04
PFHxS*	0.02	0.07	0.01	0.02	0.03
ADONA*	0.01	0.04	0.00	0.00	0.01
6:2 FTS*	0.03	0.29	0.02	0.03	0.09
PFOA	0.10	0.11	0.09	0.10	0.10
PFHpS*	0.00	0.05	0.00	0.00	0.01
PFNA	0.08	0.07	0.05	0.06	0.06
PFOS*	0.05	0.07	0.05	0.05	0.06
9Cl-PF3ONS*	0.05	0.05	0.03	0.04	0.04
8:2 FTS*	0.07	0.08	0.07	0.07	0.07
PFDA	0.08	0.04	0.03	0.05	0.05
PFUnA	0.08	0.05	0.07	0.07	0.07
11Cl-PF3OUdS*	0.09	0.06	0.03	0.05	0.06
PFDoA	0.09	0.11	0.08	0.07	0.09

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage 2025